Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to ...

Having secured one of last year’s largest funding rounds, Formation Bio is eyeing up to 545 million euros from a licensing deal with Sanofi.

The AI in Life Science Market is anticipated to experience a remarkable compound annual growth rate (CAGR) of around 25% in ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Sanofi buys a drug from Dren Bio to claim a stake in the emerging field of deep B-cell depletion for autoimmune diseases.

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

Westlake and Ascend close plants, Chemify opens AI-robotics lab, Formation licenses gusacitinib to Sanofi, and more ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.